Trademark: 77820259
Status Date
Monday, May 27, 2013
Filing Date
Friday, September 4, 2009
Published for Opposition
Tuesday, February 2, 2010
Abandoned Date
Monday, May 27, 2013
5 Pharmaceutical preparation of chemically modified oral calcitonin for the treatment of osteoporosis, osteoarthritis, Paget disease, hypercalcemia, fibromyalgia, osteoporotic fracture pains and bone fracture pains, peripheral and neuropathic pains, obesity, migraine headaches, bone mineral loss, calcinosis, and postmenopausal breast cancer (as an aromatase inhibitor)
May 28, 2013
Abandonment Notice Mailed - No Use Statement Filed
May 27, 2013
Abandonment - No Use Statement Filed
Nov 1, 2012
Notice Of Approval Of Extension Request E-Mailed
Oct 31, 2012
Extension 5 Granted
Oct 26, 2012
Extension 5 Filed
Oct 26, 2012
Teas Extension Received
May 23, 2012
Notice Of Approval Of Extension Request E-Mailed
May 22, 2012
Extension 4 Granted
Apr 12, 2012
Extension 4 Filed
Apr 12, 2012
Teas Extension Received
Oct 14, 2011
Notice Of Approval Of Extension Request E-Mailed
Oct 13, 2011
Extension 3 Granted
Oct 11, 2011
Extension 3 Filed
Oct 11, 2011
Teas Extension Received
Apr 22, 2011
Notice Of Approval Of Extension Request E-Mailed
Apr 21, 2011
Extension 2 Granted
Apr 19, 2011
Extension 2 Filed
Apr 19, 2011
Teas Extension Received
Nov 2, 2010
Notice Of Approval Of Extension Request E-Mailed
Nov 1, 2010
Extension 1 Granted
Oct 13, 2010
Extension 1 Filed
Oct 28, 2010
Case Assigned To Intent To Use Paralegal
Oct 13, 2010
Teas Extension Received
Apr 27, 2010
Noa Mailed - Sou Required From Applicant
Feb 2, 2010
Official Gazette Publication Confirmation E-Mailed
Feb 2, 2010
Published For Opposition
Dec 28, 2009
Law Office Publication Review Completed
Dec 28, 2009
Assigned To Lie
Dec 8, 2009
Approved For Pub - Principal Register
Dec 8, 2009
Assigned To Examiner
Sep 9, 2009
New Application Office Supplied Data Entered In Tram
Sep 8, 2009
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
